Differences on Quality of Life of Patients with Schizophrenia: A Multicentric Study from Three Latin-America Countries.
Differences
Latin-America
Quality of life
Schizophrenia
Journal
Culture, medicine and psychiatry
ISSN: 1573-076X
Titre abrégé: Cult Med Psychiatry
Pays: Netherlands
ID NLM: 7707467
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
5
1
2019
medline:
4
12
2019
entrez:
5
1
2019
Statut:
ppublish
Résumé
The aim of the study is to explore the variation on patient's Quality of Life (QoL) across three Latin-Americans countries. The study included 253 stabilized outpatients with schizophrenia from three Mental Health Services in Bolivia (N = 83), Chile (N = 85) and Peru (N = 85). Patients' were assessed using Schizophrenia Quality of Life Questionnaire (SQoL18). We collected socio-demographic information and clinical data, while recognizing the cultural complexity/dynamics of each country, and the influence of cultural contexts on how people experience the health systems. There are differences in QoL according to each country. Peru reports better levels of QoL at the Total Score Index and in most of the dimensions of the SQoL18. Bolivia shows the lowest indicators of QoL, except, interestingly, for the Resilience dimension where it reaches the highest scores. Even when the studied regions in the three Latin American countries share several cultural characteristics, there are also some important differences between them on patients' QoL. Possible disparities at investment in mental health by the Governments of each country are discussed while possible influences of (inter)cultural contexts are taken into account.
Identifiants
pubmed: 30607876
doi: 10.1007/s11013-018-9618-3
pii: 10.1007/s11013-018-9618-3
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
326-335Subventions
Organisme : Universidad de Tarapacá
ID : Proyecto Mayor de Investigación Científica y Tecnológica UTA n°3732-16.
Références
Pharmacoeconomics. 1997 Jan;11(1):32-47
pubmed: 10172917
BMC Psychiatry. 2006 Sep 19;6:39
pubmed: 16984637
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
Psychiatr Serv. 2008 Mar;59(3):232-4
pubmed: 18308900
Soc Psychiatry Psychiatr Epidemiol. 2011 Aug;46(8):685-93
pubmed: 20490455
Behav Res Ther. 2010 Sep;48(9):883-9
pubmed: 20538264
Schizophr Res. 2010 Aug;121(1-3):241-50
pubmed: 20541912
Compr Psychiatry. 2011 Mar-Apr;52(2):171-80
pubmed: 21295224
Int J Soc Psychiatry. 2013 Feb;59(1):93-100
pubmed: 21971984
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):343-9
pubmed: 23763531
Int J Ment Health Syst. 2014 May 15;8:18
pubmed: 24843384
Int J Soc Psychiatry. 2015 Feb;61(1):82-91
pubmed: 25085414
Schizophr Res. 2014 Oct;159(1):136-43
pubmed: 25212841
Sci Rep. 2015 Dec 03;5:17650
pubmed: 26632639
Curr Opin Psychiatry. 2016 May;29(3):218-23
pubmed: 26998939
Acta Psychiatr Scand. 2016 Oct;134(4):360-7
pubmed: 27497263
J Ment Health. 2017 Feb 28;:1-7
pubmed: 28635432
Am J Orthopsychiatry. 1987 Jul;57(3):316-331
pubmed: 3303954
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994 Jul-Aug;22(4):171-7
pubmed: 7810373